

JOURNAL FOR CLINICAL STUDIES

Your Resource for Multisite Studies & Emerging Markets





MEDIA INFORMATION 2022

www.journalforclinicalstudies.com

OUR BRAND

Our contribution to the Industry

The Pharmaceutical Industries' vision to bring a cure for all, the need to bring medicines to market faster, and the intention to make healthcare available to all has seen trials being conducted in many locations. The access to patients with a varied gene pool, food and cultural habits and population exposed to specific diseases has seen regions like India, China, Africa, Middle East and Latin America become major sites for sponsor companies to conduct their clinical trials. As with all global operations, operating under different regulatory guidelines, understanding different cultural and ethical values and finding the right partners, has remained a challenge for pharmaceutical, bio-pharmaceutical and medical device companies. JCS with its distinguished editorial advisory board provides you with the best practice guidelines for conducting global clinical trials. We are the specialist journal providing you with relevant articles which will help you to navigate emerging markets.



Our Focus

Our authors – who share their knowledge and offer practical experiences with our readers – are executives, managers, and investigators who are involved in every stage of clinical trials from study design and protocol development, to data management, subject recruitment, budget negotiations, and site monitoring.

Our Readers


With a global audience of **41,500*** engaged clinical professionals, Journal for Clinical Studies connects you to the industry professionals who are most receptive to your marketing message.

OUR EXPERTS



Deborah A. Komlos

Deborah A. Komlos, MS, is the US correspondent for Journal for Clinical Studies. Deborah is the Senior Medical & Regulatory Writer for the Cortellis Regulatory Intelligence US module at Clarivate Analytics. In this role, her coverage centres on FDA advisory committee meetings, workshops, and product approvals. Deborah's columns and blogs are always timely, interesting and invaluable for clinical trial professionals.



Dr. Hermann Schulz

Dr. Hermann Schulz, is the Europe correspondent for Journal for Clinical Studies. Dr Schulz holds an MD (Barcelona and Munich) as well as an MBA in Business Administration (Zurich). Dr. Hermann Schulz is a Visiting Professor, Clinical Pharmacology and Pharmaceutical Medicine, Universities of Duisburg/Essen and Witten-Herdecke and also the Founding Member of the International Association of Central Laboratories IACL, London. With his extensive knowledge of the Clinical Trials arena, Dr Schulz advises and contributes thought leadership articles within JCS.



Lucy Robertshaw

Lucy Robertshaw is a contributor and member of the Editorial Advisory Board for Journal for Clinical Studies. Lucy has many years of experience of working with AstraZeneca, Lucy is a member of the American Women's Club in Stockholm, where she loves to meet likeminded people and enjoy her passion for networking. Through this networking Lucy provides insights and interviews from clinical trials experts, reporting from conferences and events, and analyses the current clinical trials market.

Journal for Clinical Studies' Editorial Advisory Board

Our Editorial Advisory Board ensures the credibility and accuracy of our content through their expertise. The Board members come from all walks of the industry – CROs, Regulatory agencies, Ministry of Health, Technology and Pharmaceutical Companies. They have experience with Clinical Trials Management, Design, GCP, Recruitment & Retention, Data management, Informed consent and other fields. These international experts offer their mastery to review manuscripts, suggest topics and advise editors on industry issues. Through their contributions, our readers benefit by receiving credible, practical and relevant articles and commentaries.



CIRCULATION & READERSHIP

In Print

JCS is a globally distributed publication with an established presence across the world. Each Bi-monthly issue has a print copy distribution figure of **24,200** copies, and digital distribution figure of **17,345**, providing strong access to the International Market. JCS is sent directly to key decision makers in the Clinical Research Industry.

READERSHIP BY JOB FUNCTION

14%	Corporate Management (Medical Directors / Medical Affairs)
14%	Research and Development (Project Management)
12%	Heads of Clinical Trials
10%	Heads of IT (Date Management / Analysis / Biostatistics)
7%	Heads of Lifesciences
7%	Logistics and Supply Chain Managers
7%	Regulatory Affairs / Compliance / Drug Safety / Pharmacovigilance
6%	Clinical research Coordinator (CRC / Study Coordinator / Research Nurse)
6%	Clinical Research Associate (CRA Monitor)
6%	GCP Auditing / OC / QA
6%	Laboratory Analysis
5%	Contracting / Procurement Officers


CIRCULATION

Print Subscribers	24,200
Digital Subscribers	17,345

DIRECT MAIL

JCS eNewsletters	17,345
e Blast	16,342

BUSINESS & INDUSTRIES




In Digital

JCS – Journal for Clinical Studies E Newsletter

– provides the latest business news, product news, events, technical papers, and links to company information and services. This gives you the regular and latest update on products and services offered to the global clinical trials industry.

JCS eCampaigns – is sent to more than **17,345** professionals working for the leading pharmaceutical companies, midsized bio technology companies, clinical research organisations, other vendors & service providers, and government & non-government agencies.



RATES & DATA

Print Media

PRINT ADVERTISEMENT

Double Page	£ 5,250
Full Page	£ 2,850
Half Page (Vertical / Horizontal)	£ 1,650
Prime Positions:	
Inside Front Cover	£ 5,950
Inside Back Cover	£ 4,850
Outside Back Cover	£ 7,250
Page Opposite Contents	£ 3,750
Page Opposite Editor's Letter	£ 3,750
1 Page Corporate Profile	£ 2,000
Front Cover LOGO	£ 1,500

Discounts apply for series bookings.

Inserts, reprints and recruitment advertisers' rates are available on application.

For more information contact: sales@pharmapubs.com

MECHANICAL SPECIFICATIONS

(In mm, Height x Width, with Type, Trim, Bleed)

	Type	Trim	Bleed
Full Page:	261 x 181	297 x 210	303 x 216
½ Pages (horizontal)	135 x 186	148 x 210	154 x 216
½ Pages (vertical)	273 x 92	297 x 105	303 x 108

Please supply digitally, ideally a press ready PDF.

Alternatively supply as a flat image file (Tiff, Jpeg, EPS, PSD etc) ensuring that all fonts are embedded, images are High-resolution and the file is CMYK.

Digital Media

WEBSITE ADVERTISEMENT

Home Page Pop-up 640 x 480 px	£2,500 for 3 mos
Corner Peel (Specs sent upon request)	£1,800 for 3 mos
Leader Board 728 x 90 px	£1,200 for 3 mos
Rectangular (right/left column) 300 x 250 px	£1,000 per 3 mos
Skyscraper (right/left column) 300 x 600 px	£1,000 per 3 mos
Host Videos	£1,000 for 3 mos
Sponsored Articles	£1,000 per 3 mos
Events Listing	£250 for 3 mos
News	£250 for 3 mos

E-Blast & E-Newsletter Campaign

JCS holds a secured database of over 17,345 professionals working for the leading pharmaceutical, midsized bio-technology companies, CRO's and other stakeholders, who have given their consent to receive a Weekly Electronic Newsletter and any 3rd party relevant supplier information. JCS provides a direct communication link to these high net worth individuals through its Electronic Campaign Platforms.

E Newsletter	£250 Per Week (Minimum of 4 weeks booking)
E Blast: HTML E Blast	£1,470 Per Campaign



DIGITAL OFFERINGS

Online Website Advertising

Display your ad in front of decision makers in the field by placing your banner advertisement on www.journalforclinicalstudies.com.

- ✓ Content Tactic: Branding/Awareness, Web Traffic



Corporate Profile Listing

Exclusive resource section on the Journal For Clinical Studies (journalforclinicalstudies.com) website where your company can disseminate collateral, videos, 900 word company descriptions, USP to drive website traffic, generate leads and more. Your content block is not an ad unit and does not go into rotation so it is visible 24/7.

- ✓ Content Tactic: Branding/Awareness, Web Traffic



MLM Medical Labs GmbH

MLM Medical Labs (MLM) is a Central Laboratory dedicated exclusively to clinical trials. MLM offers full laboratory services, including a whole range of analytics: standard safety profiles, such as blood counts, coagulation, urinalysis and clinical chemistry, and analyses of biomarkers, drug compounds, metabolites and molecular diagnostic parameters. Internationally active for 25 years in over 40 countries MLM is located in Monchengladbach, Germany. The MLM lab is on duty 365 days a year to ensure valid results with a quick turnaround time. Highly skilled with extensive clinical lab experience, our 60-person team supports over 140 clinical studies, phase I-IV at any given time. MLM Medical Labs runs trials in a broad range of indications, including diabetes, cancer, infectious diseases, dermatology, and diseases affecting the cardiovascular, neurological and immunological system.

All members of the technical staff are certified research or medical assistants. 50% of the team has degrees in chemistry, biochemistry, biology or physiology and a third have completed PhDs in relevant fields.

MLM's customers are renowned CROs and companies in the biotech and pharmaceutical industries in Europe, Asia and the U.S. To fully support this worldwide client base, we've developed an outstanding level of flexibility and dedicated ourselves to high-quality results delivered promptly. In 2015 MLM forged a strategic alliance with Cenetro Central Laboratories, located in Austin Texas, USA in order to offer seamless laboratory testing for European and North American client sites.

Analytics

- > Development and validation of analytical methods
- > Broad portfolio of validated biomarker assays
- > World-standard analytical methods
- > Clinical chemistry, haematology, coagulation, serology and urine analysis
- > Complete analytical study reports

Management and Logistics

- > Global study setup and project management
- > In-house manufacturing of study-specific sampling kits: MLM Kit Building®
- > More than 2700 sqm lab space
- > Worldwide transport of clinical samples, sampling kits and supplies
- > Long term sample storage at -30 °C, -80 °C and cry conservation: MLM Smart Storage System®

Superior IT Infrastructure

- > Online data-access and kit tracking: MLM online®
- > MLM Smart Storage System® for safe and stable long term storage on a daily costs basis
- > Electronic data transfer according to client's DTA specification

Website: www.mlmlabs.com

Ad Retargeting

Once a visitor leaves jforcs.com, your display ad will follow them across the web, driving targeted groups to your website to learn more about your products or services.

- ✓ Content Tactic: Branding/Awareness, Web Traffic



DIGITAL OFFERINGS

BOOST – Custom Targeted Email Campaign

BOOST is a highly targeted, data driven, HTML E-Campaign tool. BOOST contains over 100,000 decision makers from global companies involved in the pharmaceutical and scientific industries served by our leading publications.

✓ Content Tactic: Web Traffic, Lead Generation

JOURNAL FOR CLINICAL STUDIES
BOOST

MYODERM DIRECT TO SITE SOLUTIONS

STRATEGIC. STREAMLINED. SMARTER.

ARE YOU USING THE BEST SOURCING, LABELING AND DISTRIBUTION FOR YOUR TRIAL?

Any company can deliver clinical supplies to your study sites. But how many can...

- Reduce or eliminate drug waste?
- Provide flexible sourcing, labeling, and distribution?
- Source from manufacturers and distributors down to the local level in more than 60 countries?
- Offer faster and more cost-effective labeling services?
- Actively adapt your sourcing strategy to keep your trial running at peak efficiency?

When it comes to delivering open label drugs to clinical study sites, no one matches Myoderm for flexibility, buying power and expert market knowledge. We are The Clinical Trial Supply Company.

CASE STUDY: SEE FOR YOURSELF

Oncology clinical trial supply is becoming increasingly more complex. An already demanding trial that required high-level logistical knowledge and had a product restriction per patient per site became more challenging when the manufacturer issued a product recall. Myoderm's experience and sourcing relationships led to a solution that resulted in waste reduction and cost savings for the client.

[DOWNLOAD NOW >](#)

CONTACT US

Ready to learn more or have questions on how Myoderm can support your next clinical trial? Contact us for more information.

Europe
+44 (0)116 3033 530
globalsales@myoderm.com

North America
+1 610 233 3300
globalsales@myoderm.com

myoderm.com

© 2019 Myoderm

Journal for Clinical Studies – E-Newsletter

JCS – E-Newsletter is published weekly to over **17,345** highly engaged clinical trials professionals. Each edition features a premium collection of news, blogs, advertising banners, events, webcasts and more.

JCS Newsletter also contains highlighted articles from the most current edition of the journal.

✓ Content Tactic: Branding/Awareness, Web Traffic

JCS WEEKLY
LATEST NEWS FROM THE WORLD OF CLINICAL TRIALS

HIGHLIGHT ARTICLES

*Expediting Clinical Trials With Cloud Based Metadata Repository And Study Automation Technologies

*Digital Adherence Modern Solutions To An Age Old Problem

*Digitising Healthcare The Challenges And Benefits

Sanofi refiles \$3.2B Translate Bio buyout with FTC to allow more time for review

Sanofi and Translate Bio are refiling paperwork on their \$3.2 billion merger to give the FTC more time to review.

AbbVie's Imbruvica patent win sets up solid growth path after Humira's decline: analyst

A federal court ruling, upholding patent protection for AbbVie's Imbruvica, is a big win for the company says Bernstein analyst Ronny Gal.

ILLINGWORTH RESEARCH GROUP
a SYNEOS HEALTH company

Our Vision
Be the best patient focused solutions company for clinical trials worldwide.

Our Mission
Bring a unique combination of services to facilitate worldwide participation in clinical trials for all

PatientGO
Powered by Fierce Research Group

FDA approval of Pfizer's COVID-19 vaccine spurs American confidence: Harris Poll

Pfizer's Comirnaty vaccine FDA approval last week boosted consumer confidence among both vaccinated and unvaccinated people.

Key vaccine leaders departing FDA as COVID-19

DIGITAL MEDIA INFORMATION

journalforclinicalstudies.com

Average E Blast CTR: 2.8

Average E Newsletter CTR: 3.2

journalforclinicalstudies.com is an online portal providing readers with peer-reviewed articles from industry experts, news bulletins, a company directory and technical white papers. Website visitors are also able to access the entire archive of JCS articles.

The location report from Google analytics (2021) reveals that over 92% of visits came from Europe, America, Asia and Middle East. The leading countries are United States, United Kingdom, Germany, France, Norway, Switzerland, Italy, China, India, UAE, Saudi Arabia and Australia.

Social Media



www.twitter.com/journalforclinicalstudies



www.facebook.com/journalforclinicalstudies

Total amount of Impressions in 2021:

18,327,628

Total amount of clicks in 2021:

57,829

Total amount of unique Impressions in 2021:

16,142,238

Total amount of unique clicks in 2021:

47,231

White Papers

journalforclinicalstudies.com presents technical white papers, highlighting each contributing organisation's expertise and knowledge within its fields. White papers appear on the site in an accessible, searchable archive, which can be easily viewed and downloaded by readers.

Digital Journal and eNewsletter

The digital magazine edition of JCS is a fully interactive, page turning version of the print magazine. The e-Journal is emailed to a growing list of digital subscribers in a regular newsletter, expanding JCS's print circulation to a broad international readership.

Company Capabilities

journalforclinicalstudies.com's online company profile listings provides a guide for readers wishing to find out more about service providers. The company listings features company contact information, along with an 800 word description, company logo and website links.

EDITORIAL CALENDAR 2022

JCS – Journal for Clinical Studies is peer reviewed. Supported by a team of industry experts, JCS brings you contemporary and authoritative articles which will guide the industry to use the best practice for regulatory issues, market analysis, drug discovery, development, drug design, clinical research, data analysis, safety and efficacy, recruitment and retention, laboratories, analytical testing, custom and contract manufacturing, primary and secondary packaging and logistics and supply chain management.

This Editorial Calendar is a Guideline only. It is subject to change according to movements in the industry. If you are interested in featuring a specific article within JCS, please email your suggestion along with a short 100 word synopsis to the editor at: editorial@senglobalcoms.com.

Peer Review Protocol

Criteria for Publication

Provides strong evidence for its conclusions. • Novel • Unbiased • Non Promotional. Of extreme importance to stakeholders in the Pharmaceutical Industry. In general, to be acceptable, a paper should represent an advance in understanding that is likely to influence thinking in the field. There should be a good and clear reason as to why the work deserves the visibility of publication in a Pharma Publications journal rather than a different journal.

Author Guidelines

A typical article will be about 2000–2500 words. You can include from 4–5 images, graphs or graphics within the article.

The article must be sent to us in a Word Document format, and all associate images should be supplied separately in a High Resolution (PDF, Jpeg, PNG) file. [300 dpi min].

Editorial Sections

include but are not limited to:

Watch Pages

Market Report

Clinical & Medical Research

Clinical Trials Supply

Central Labs & Core Labs

Laboratories

Data Management

Regulatory Guidelines

Therapeutics

Analytical Testing

Manufacturing & Packaging

Recruitment & Retention

Innovations

Investment & Finance

Article Title: Should not be more than 10 words in length.

Author Bios: Author Bios should not be more than 60 words in length. Please also supply us with the Author(s) Email.

Author Picture(s): Please send Author(s) Headshots in High Resolution (300 dpi min), (Jpeg, PDF format)

Please visit our website journalforclinicalstudies, or request from our editorial team the entire Peer Review Protocol, and the Author Guidelines.

EDITORIAL CALENDAR 2022

January

Volume 14 Issue 1

Issue Date:	25 th January 2022
Editorial Submission Deadline:	10 th December 2021

Market Reports

- Country Focus: UK, EU, Scandinavia
- Globalising clinical trials
- The promise of a reporting system in patient safety
- Emerging role of bioinformatics tools in the evolution of clinical research
- Medical writing

Clinical & Medical Research

- Medical device & trials
- Increasing the industries sustainability by using patient inspired solutions
- Artificial intelligence in clinical & medical research
- Late phase trials

Therapeutics

- CNS
- Focus on: Schizophrenia / Depression
- Reproductive & maternal health
- Pediatric

Clinical Trials Materials Management

- Comparator drug supply
- Named patient programmes
- Assessing of study design and matching to systems based on efficiency & cost

Technology

- E-clinical technologies
- Translation services
- IVRS/IWRS

Logistics & Supply Chain

- Sample management
- Sourcing and procurement
- Optimisation and cost management

March

Volume 14 Issue 2

Issue Date:	25 th March 2022
Editorial Submission Deadline:	10 th February 2022

Market Reports

- Country Focus: Australia & New Zealand, India, China
- Risk based monitoring
- FSP versus full service
- Clinical trials insurance
- Global outsourcing and vendor management

Clinical & Medical Research

- Guiding the clinical trials industry in Digital Health
- Strategic alignment of study objectives and endpoints to drive value and fill data gaps
- The increasing inclusion of biomarkers as an eligible criterion for participation in clinical trials.
- Responsibilities of the sponsor and the monitor

Therapeutics

- Paediatrics
- Oncology in paediatrics
- Obesity
- Respiratory (COPD)

Clinical Trials Materials Management

- Randomization and blinding
- Handling of and accountability for pharmaceutical products for trial
- Termination of trial – Returns & destruction

Technology

- Monitoring, auditing and inspection
- Record-keeping and handling of data
- Information for subjects and informed consent
- Adverse event reporting

Logistics & Supply Chain

- Temperature controlled shipment
- Multinational logistics service networks
- Instruction for compliant submissions offered in US & Europe

EDITORIAL CALENDAR 2022

May

Volume 14 Issue 3

Issue Date:	25 th May 2022
Editorial Submission Deadline:	10 th April 2022

Market Reports

- **Country Focus:** Singapore, Japan, Thailand, China, South Korea, Malaysia
- Site selection
- Pharmacovigilance & risk management
- Clinical trials reimbursement
- Training and capacity building

Clinical & Medical Research

- Guiding the clinical trials industry in digital health – dissecting digital health data collection methodologies
- Strategic alignment of study objectives and endpoints to drive value and fill data gaps
- The increasing inclusion of biomarkers as an eligible criterion for participation in clinical trials
- Assessing complexity of study design and matching to systems based on efficiency and cost-effectiveness

Therapeutics

- CNS Disease – Focus on: Alzheimer's / Dementia
- Cardiovascular
- Obesity & metabolic

Clinical Trials Materials Management

- Clinical trials packaging & labelling
- Multi-tenant cloud platform to manage, track and report clinical trial activities
- Improvements through ERP

Technology

- Big data and AI initiatives changing the competitive landscape
- The 'beyond the pill' model: apps and wearable devices
- The electronic laboratory notebooks: addressing data security and privacy concerns
- Using advanced analytics and language processing capabilities to deliver clinical decision support

Logistics & Supply Chain

- Clinical trials logistics
- The security of patient data in digital supply chains
- RFID and NFC tags the blockchain promise
- Cardiovascular safety

July

Volume 14 Issue 4

Issue Date:	25 th July 2022
Editorial Submission Deadline:	10 th June 2022

Market Reports

- **Country Focus:** USA, Canada, Latin America
- Imaging Labs / Central Labs / ECG & Core Labs
- Late stage research (II-IV)
- Patient recruitment & retention
- Medical writing

Clinical & Medical Research

- Patient centricity in support of clinical operations and study adherence
- The importance of subject recruitment and retention to clinical trial success
- Unique challenges and opportunities in orphan diseases
- Outsourcing and collaborative research in clinical trials

Therapeutics

- Food borne
- Bacterial & mycotic
- Ophthalmology
- Diabetes

Clinical Trials Materials Management

- Clinical trials packaging & labelling
- Multi-tenant cloud platform to manage, track and report clinical trial activities
- Improvements through ERP

Technology

- EDC – Data Capture & Evaluation
- The rise of virtual drug design tools
- Virtual screening and database building
- Scientific apps in the labs
- The 3D printed pill technology

Logistics & Supply Chain

- Building a patient-centric supply chain
- Integrating cybersecurity solutions
- Supply chain meets blockchain innovation
- Temperature control – innovative solutions
- Advancements in GPS tracking options GDP requirements: the understanding and application of Quality Risk Management (QRM)

EDITORIAL CALENDAR 2022

September Volume 14 Issue 5

Issue Date:	25 th September 2022
Editorial Submission Deadline:	10 th August 2022

Market Reports

- **Country Focus:** Sub Saharan Africa, South Africa, Middle East & North Africa
- Early phase (I & II)
- Remote data acquisition & analysis
- Medical writing
- Translation services

Clinical & Medical Research

- Application challenges of the new EU Clinical Trial Regulation
- Early phase trials
- Future perspectives and innovations in clinical studies
- FDA Post-marketing safety surveillance program for drug and therapeutic biologic products

Therapeutics

- Rare disease
- Infectious diseases
- Oncology
- Vaccine development

Clinical Trials Materials Management

- Comparator drug supply
- Named patient programmes
- Assessing of study design and matching to systems based on efficiency & cost.

Technology

- ePRO, BOYD, eCOA, eCTD
- CDISC / CDASH
- Data management & biometrics

Logistics & Supply Chain

- New approaches in pharma logistics
- Securing the Pharma Supply chain: the current challenges
- Sourcing and procurement
- Optimisation and cost management
- Logistics control in extreme weather conditions

November Volume 14 Issue 6

Issue Date:	25 th November 2022
Editorial Submission Deadline:	10 th October 2022

Market Reports

- **Country Focus:** Russia, CEE States, CIS States, Central Europe
- The new EU clinical trials regulations
- Use of Investigative sites in Central & Eastern Europe.
- RIB & Ethics review board
- Risk based monitoring
- Training and education

Clinical & Medical Research

- Evaluating needs and available in-house resources for managing data and regulatory documentation
- Pharmacogenomics & personalised medicine
- Biomarkers & biosimilars
- Study oversight models and quality / risk management systems

Therapeutics

- Rare disease
- Infectious diseases
- Oncology
- Vaccine development

Clinical Trials Materials Management

- Building effective teams in the clinical trial schematic
- Supply and Storage
- Investigational labelling and packaging

Technology

- EDC – Data capture & evaluation
- The rise of virtual drug design tools
- Virtual screening and database building
- Scientific apps in the labs

Logistics & Supply Chain

- Sample management
- Sourcing and procurement
- Optimisation and cost management

Contact:

Journal for Clinical Studies
46 Plover Way, London SE16 7TT,
United Kingdom

T: +44 (0) 204 5417569
E: info@senglobalcoms.com
W: journalforclinicalstudies.com

Advertising Contact:

Ty Eastman, ty@senglobalcoms.com

Editorial:

Beatriz Romao, beatriz@senglobalcoms.com

Subscriptions:

Jessica Dean-Hill, jessica@senglobalcoms.com